ADALIMUMAB

Brand name:

• Hadlima®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Condition/indication:
(therapeutic use)

• Severe active rheumatoid arthritis; Severe psoriatic arthritis; Ankylosing spondylitis; Severe chronic plaque psoriasis; Juvenile idiopathic arthritis; Severe crohn’s disease; Refractory fistulising crohn’s disease; moderate to severe hidradenitis suppurativa

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC submission type:

Change to listing (Minor)

Comment:

--

Submission sponsor:

Merck, Sharp & Dohme (Australia) Pty Ltd

Other PBAC consideration:

--

Submission received for:

July 2020 PBAC meeting

Opportunity for consumer comment:

Open 29/04/2020 and close 10/06/2020 (see PBS Website)

PBAC meeting:

Held on 08/07/2020

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

30/10/2020

Lodgement of required documentation:

11/11/2020

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 18/11/2020

Status:

Finalised

Government processes:

Commenced on 01/02/2021

Medicine listed on the PBS:

01/04/2021 (see PBS schedule)

---